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Background: Polypharmacy is often considered suggestive of suboptimal prescribing, and is associated with
adverse outcomes. It is particularly common in the context of cardiovascular disease, but it is unclear whether
prescribing of multiple cardiovascular medicines, which may be entirely appropriate and consistent with clinical
guidance, is associated with adverse outcome. The aim of this study was to assess the relationship between
number of prescribed cardiovascular medicines and unplanned non-cardiovascular hospital admissions.
Methods: A retrospective cohort analysis of 180,815 adult patients was conducted using Scottish primary care
data linked to hospital discharge data. Patients were followed up for one year for the outcome of unplanned
non-cardiovascular hospital admission. The association between number of prescribed cardiovascular medicines
and hospitalisation was modelled using logistic regression, adjusting for key confounding factors including
cardiovascular and non-cardiovascular morbidity and non-cardiovascular prescribing.
Results: 25.4% patients were prescribed ≥1 cardiovascular medicine, and 5.7% were prescribed ≥5. At least one
unplanned non-cardiovascular admission was experienced by 4.2% of patients. Admissions were more common in
patients receiving multiple cardiovascular medicines (6.4% of patients prescribed 5 or 6 cardiovascular medicines)
compared with those prescribed none (3.5%). However, after adjusting for key confounders, cardiovascular
prescribing was associated with fewer non-cardiovascular admissions (OR 0.66 for 5 or 6 vs. no cardiovascular
medicines, 95% CI 0.57-0.75).
Conclusions: We found no evidence that increasing numbers of cardiovascular medicines were associated with an
increased risk of unplanned non-cardiovascular hospitalisation, following adjustment for confounding. Assumptions
that polypharmacy is hazardous and represents poor care should be moderated in the context of cardiovascular
disease.
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Polypharmacy is widely considered as the prescribing of
multiple medications, is often perceived to be inappropri-
ate, and appears to be increasing in prevalence [1]. Al-
though no single agreed definition exists for polypharmacy
[2], and it may be thought of as either appropriate or prob-
lematic, the total number of medicines has nonetheless
been identified as a patient characteristic associated with* Correspondence: rap55@medschl.cam.ac.uk
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unless otherwise stated.high risk prescribing [2]. A number of undesirable out-
comes are associated with polypharmacy, including adverse
drug events [3], increased mortality [4], poor adherence to
treatment [5] and impaired quality of life [6]. Polyphar-
macy has also been found to be a strong predictor of pre-
ventable medicine-related hospital admissions [3], as well
as unplanned hospitalisation more generally [4,5]. On-
going care of patients with long-term conditions in the UK
usually falls to the general practitioner (GP), often requir-
ing coordinating the use of multiple medicines; the UK
performance-related pay scheme, the Quality Outcomes
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of multiple medicines.
Cardiovascular disease (CVD) is one area where poly-
pharmacy may be of particular relevance. CVD is the
leading cause of death globally [6], and associated poly-
pharmacy is common, driven by numerous evidence-based
guidelines advocating treatment with multiple therapeutic
drug classes [7-9]. Indeed, in the UK cardiovascular medi-
cines account for £1.35 billion annually, or 15% of the total
primary care prescribing budget [10].
Despite the clear burden of cardiovascular disease and
the volume of medications used in its management it re-
mains unclear, however, whether prescribing of multiple
cardiovascular medicines, which may well be entirely
appropriate and in keeping with current evidence and
guidance, is necessarily still associated with adverse out-
comes. Polypharmacy is often considered simplistically
as multiple medicines, irrespective of clinical appropri-
ateness, and therefore we decided to examine whether
this was proper. We decided to examine the potential im-
pact of polypharmacy on unplanned hospital admissions,
as a general measure of quality of care. Whereas routine
hospital admissions or outpatient attendances may be
considered appropriate measures in the management of
long-term conditions, unplanned hospitalisation is gener-
ally undesirable. We hypothesised that increasing num-
bers of cardiovascular medicines might lead to unplanned
hospital admission, through adversely impacting upon
medication adherence, as well as contributing to medica-
tion errors, interactions and adverse events. We also con-
sidered that polypharmacy may reflect a failure to use
medications in a rationale and effective manner, and as
such may reflect poorer care more generally, again con-
tributing to unplanned admissions. It was decided to spe-
cifically examine non-cardiovascular admissions, as we did
not believe it would be possible to tease out any adverse
or beneficial effects of cardiovascular medication from
underlying cardiovascular disease severity.
The aim of this study was therefore to examine whether
cardiovascular polypharmacy was associated with un-
planned non-cardiovascular hospital admissions.
Methods
We conducted a retrospective cohort study using data
from forty GP surgeries involved in the Scottish Practice
Team Information project. This is a programme providing
information on national morbidity trends and primary
care activity, and the surgeries involved are considered to
be reasonably representative of the Scottish population as
a whole [11]. Primary care data on patient demographic
characteristics, diagnostic codes and electronic prescrib-
ing, were probabilistically linked to national Scottish acute
hospital in-patient admissions records (the Scottish Mor-
bidity Record). These data are considered of good qualityduring the relevant time period [12], and exclude accident
and emergency department visits, and psychiatry and ma-
ternity admissions.
Patient details were based on data recorded as of 1
April 2006. All adults (aged ≥20 years) registered per-
manently with a surgery were included in the analysis.
We recorded the presence of up to 40 long-term phys-
ical and mental health problems from the GP data. This
list was developed by expert consensus, aiming to cap-
ture conditions significantly affecting quality of life, and
those associated with high rates of morbidity or death.
The list of conditions included a number of cardiovascu-
lar or cardiovascular-related problems: ischaemic heart
disease, stroke (or transient ischaemic attack, TIA), car-
diac failure, hypertension, atrial fibrillation and diabetes.
Details of the development of this morbidity list are de-
scribed elsewhere [13].
GP prescribing data was split into counts of cardiovas-
cular and non-cardiovascular medicines, based on categor-
isation by the British National Formulary. We included
prescriptions available on the index date for repeated issue
to the patient (and issued at least once within the previous
12 months), in addition to recently issued one-off pre-
scriptions (issued no earlier than the duration of prescrip-
tion (usually 1-2 months) prior to the index date). Where
more than one prescription of the same chemical entity
was available, these prescriptions were counted only once;
different chemical entities within the same drug class were
counted separately. There is no consistent definition of
polypharmacy, and treating the medication count as a
simple binary factor has been shown to be unhelpful [14].
We therefore categorised the cardiovascular medicine
count as none, 1 or 2, 3 or 4, 5 or 6, and 7 or more, and
the non-cardiovascular medicine count as none, 1 to 3, 4
to 6, 7 to 9, and 10 or more, as a means of capturing the
potentially non-linear nature of a medication count. Count
categories were pragmatically chosen to provide 5 separate
similarly-spaced groups for both cardiovascular and non-
cardiovascular medicines. Because of the key, centralised
position of general practice within the UK health system,
we expect to have captured the majority of prescribing for
long-term conditions, even when originally initiated in
secondary care. We are, however, unable to account for
over-the-counter treatments and short courses of treat-
ment in hospital which have not been continued subse-
quently in the community.
All patients selected were followed up for one year from
1 April 2006 for the occurrence of at least one unplanned
hospital admission. We included only admissions where
the primary diagnosis was not a cardiovascular one (i.e.
we excluded admissions with primary diagnosis ICD-10
codes I00 to I25), to avoid the potentially confounding
problem of capturing admissions due to the condition for
which the medication was being prescribed.
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scribing, and assuming an admission rate of 4% in the
baseline group (no drugs) and a stepwise relative change
in admissions of 5% per increasing prescribing category,
the study population provides over 90% power at the 5%
significance level (two-sided) to detect an overall associ-
ation between prescribing category and admission.
Statistical analysis
Statistical analysis was performed using Stata v11.2 (Stata-
Corp, Texas, USA). Mixed-effect binary logistic regression
was used to model hospital admission for a primary non-
cardiovascular problem, with count of cardiovascular med-
icines as the exposure of interest. Adjustment was made
for sex, age group (20-year age ranges), an area-based so-
cioeconomic deprivation measure (quintiles of the Scottish
Index of Multiple Deprivation, SIMD), count of non-
cardiovascular conditions, count of non-cardiovascular
medicines, and the presence of certain cardiovascular
conditions (ischaemic heart disease, heart failure, stroke
including transient ischaemic attack, peripheral vascular
disease, hypertension and atrial fibrillation). We also in-
cluded a random effect for GP surgery to account for
potential clustering of prescribing and admission char-
acteristics by this factor.
One could argue that the effect of cardiovascular con-
ditions amongst patients not receiving appropriate medi-
cines may be different from that in those patients being
treated. If so there may be some residual confounding in
the model described above. In order to overcome this
we conducted an additional more complex analysis, in-
cluding interactions between the specific cardiovascular
conditions and the cardiovascular medicine count. Ex-
ploratory analysis suggested that using interaction terms
with the full 5-category drug count variable (as used in
the non-interaction model) provided no further informa-
tion than using a simple binary variable indicating pres-
ence or absence of any cardiovascular drug. We therefore
present the results of a model using the more parsimoni-
ous parameterisation for the interaction term only (i.e. a
model containing a single interaction between a binary
variable indicating the presence of at least one cardiovas-
cular drug and 6 binary variables representing the pres-
ence of each of the cardiovascular conditions – a total of 6
interaction terms).
We conducted a number of sensitivity analyses to check
the robustness of our findings. We substituted cardiovas-
cular medicine count in the main model with a count of
eight different cardiovascular drug classes (ACE inhibitor
or angiotensin receptor antagonist, beta-blocker, calcium
channel blocker, diuretic, nitrate, anticoagulant or anti-
platelet agent, lipid lowering drug, and any other cardio-
vascular medicine), to ensure that the means of classifying
cardiovascular polypharmacy did not affect the results. Toexplore the impact of using an alternative approach to
classifying cardiovascular morbidity, we included only the
two commonest cardiovascular diseases (ischaemic heart
disease and stroke) and the two commonest risk factors
(hypertension and diabetes) as separate binary fixed ef-
fects, and included the other cardiovascular morbidities
(heart failure, atrial fibrillation, peripheral vascular disease)
in our “non-cardiovascular” morbidity count. Finally, to
exclude the potential that excessive death might result
in an apparent reduction in hospitalisation, we repeated
the analysis excluding those with death within 6 months
of admission (death data was unavailable for the full
12 months).
Results
All 180,815 adult patients from the dataset were included
in the analysis (Table 1). The study population had a
median age of 49 years (inter-quartile range, IQR 36 to
63 years) and 49.3% of patients were male. The most com-
monly recorded cardiovascular conditions were hyperten-
sion (20.4%) and ischaemic heart disease (6.8%). Just
under 60% of patients had at least one non-cardiovascular
co-morbidity, with 5.3% having 5 or more. Slightly over
a half of patients were prescribed at least one non-
cardiovascular medicine, and 2.9% were prescribed 10
or more.
A quarter (25.4%) of patients were prescribed cardio-
vascular medicines, with 5.7% prescribed 5 or more
(Table 1). Cardiovascular medicines were prescribed in
greater numbers in older patients, the most socioeco-
nomically deprived, those with greater numbers of non-
cardiovascular co-morbidities and patients prescribed
more non-cardiovascular medicines. With the exception
of peripheral vascular disease, over half of patients with
a specific cardiovascular condition were prescribed 3 or
more cardiovascular medicines.
A total of 7624 patients (4.2%) experienced at least
one unplanned non-cardiovascular hospital admission.
Admission was more common in older and more de-
prived patients, and in those with greater numbers of
recorded non-cardiovascular morbidities and those pre-
scribed higher numbers of non-cardiovascular medi-
cines (Additional file 1: Table S1). Figure 1 shows how
unplanned non-cardiovascular admissions were more
frequently observed in those prescribed multiple (7 or
more) cardiovascular medicines compared with those
prescribed none (8.8% vs. 3.5%).
The main multivariable logistic regression models are
presented in Table 2, and show that male sex, and increas-
ing age, socioeconomic deprivation, non-cardiovascular
morbidity and numbers of non-cardiovascular medicines,
were all independently associated with increased admis-
sions. The presence of hypertension was associated with
fewer unplanned admissions (OR 0.74, 95% CI 0.69-0.80).
Table 1 Number of cardiovascular medications by different patient characteristics
Percentage of patients in each group on different numbers
of cardiovascular drugs
Number of patients
(% of total)
None 1 or 2 3 or 4 5 or 6 7 or more
All patients 180815 74.6% 11.9% 7.8% 4.0% 1.7%
Gender
Female 91739 (50.7%) 72.7% 14.1% 8.0% 3.7% 1.6%
Male 89076 (49.3%) 76.6% 9.7% 7.6% 4.2% 1.9%
Age, years
20 to 39 55901 (30.9%) 97.7% 2.0% 0.3% 0.1% 0.02%
40 to 59 68525 (37.9%) 83.0% 10.7% 4.1% 1.5% 0.6%
60 to 79 45133 (25.0%) 46.1% 21.9% 17.9% 9.8% 4.3%
80 or more 11256 (6.2%) 23.4% 29.1% 26.8% 14.4% 6.2%
Deprivation quintile
1, least deprived 31121 (17.2%) 78.8% 10.8% 6.5% 2.8% 1.0%
2 37261 (20.6%) 75.3% 12.1% 7.6% 3.6% 1.4%
3 45823 (25.3%) 73.6% 12.3% 8.1% 4.1% 1.8%
4 36098 (20.0%) 72.7% 12.4% 8.4% 4.4% 2.0%
5, most deprived 30512 (16.9%) 73.2% 11.8% 8.1% 4.7% 2.3%
Cardiovascular condition
Hypertension 36859 (20.4%) 12.7% 35.9% 30.0% 14.9% 6.5%
IHD 12353 (6.8%) 4.8% 11.5% 31.1% 33.0% 19.6%
Stroke/TIA 5800 (3.2%) 10.9% 21.8% 32.6% 22.7% 12.0%
PVD 5473 (3.0%) 28.6% 21.7% 22.7% 17.1% 9.8%
Atrial fibrillation 3919 (2.2%) 7.8% 15.6% 27.7% 27.3% 21.6%
Heart failure 3673 (2.0%) 5.1% 14.2% 26.3% 29.6% 24.9%
Non-cardiovascular comorbidity
count
None 74230 (41.2%) 90.6% 5.3% 2.8% 1.1% 0.3%
1 44184 (24.4%) 77.3% 11.5% 7.0% 3.1% 1.1%
2 27199 (15.0%) 64.1% 16.6% 11.5% 5.6% 2.3%
3 16217 (9.0%) 53.1% 20.5% 14.7% 8.1% 3.6%
4 9357 (5.2%) 44.8% 23.5% 16.6% 10.2% 5.0%
5 or more 9628 (5.3%) 34.3% 26.3% 19.6% 12.5% 7.3%
Non-cardiovascular drug count
None 87702 (48.5%) 89.8% 5.9% 3% 1% 0.3%
1 to 3 61015 (33.7%) 70.1% 14.4% 9.3% 4.5% 1.7%
4 to 6 19311 (10.7%) 47.4% 22.3% 16.4% 9.7% 4.2%
7 to 9 7549 (4.2%) 35.6% 24.7% 20.3% 12.5% 6.9%
10 or more 5238 (2.9%) 29.4% 27.6% 21.2% 13.2% 8.6%
IHD, ischaemic heart disease; TIA, transient ischaemic attack; PVD, peripheral vascular disease.
Appleton et al. BMC Family Practice 2014, 15:58 Page 4 of 8
http://www.biomedcentral.com/1471-2296/15/58Other cardiovascular conditions were either not associ-
ated with hospitalisation, or showed modest positive asso-
ciations with admission; the most marked effects were for
stroke (OR for unplanned admission 1.81, 95% CI 1.65-
1.99). There was strong evidence (p < 0.001) that pre-
scribing of cardiovascular medicines was independentlyassociated with a smaller risk of unplanned hospitalisa-
tion (in contrast to the positive association observed in
the crude analysis); the strongest effect was observed for
5 or 6 cardiovascular medicines compared to none (OR
0.66, 95% CI 0.57-0.75). This is shown graphically in
Figure 2.
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Figure 1 Percentage of patients admitted to hospital. Percentage of patients experiencing an unplanned non-cardiovascular hospital
admission, for a given number of cardiovascular medicines.
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action effect between each cardiovascular condition and
the presence or absence of at least one cardiovascular
medicine are shown in Additional file 1: Table S2. As a re-
sult of including the interaction term, the effect of number
of cardiovascular medicines relative to no cardiovascular
medicines varies according to which cardiovascular condi-
tions patients have. We instead present the odds ratios for
a baseline of 1 or 2 medicines (and do not consider those
patients taking no cardiovascular medicines) which is con-
sistent across cardiovascular conditions due to the par-
ticular specification of the interaction term. Compared to
the simple model, the effect size of cardiovascular medi-
cine count was attenuated, although the negative associ-
ation with hospitalisation persisted. This is because the
effect of cardiovascular conditions amongst patients not
taking cardiovascular medicines is generally greater than
in those patients who are taking them (Additional file 1:
Table S3).
The sensitivity analyses demonstrated that our results
were robust to the definition of cardiovascular drug
count used, the categorisation of long-term conditions,
and the exclusion of deaths (data not shown).
Discussion
This study examined the question of whether high levels
of cardiovascular polypharmacy might be associated with
adverse non-cardiovascular consequences, as measured
by unplanned hospitalisation. Our study confirmed that
cardiovascular polypharmacy is common, with 13.5% of
all adult patients prescribed at three of more such medi-
cines. Crudely, those patients taking more cardiovascular
medicines are more likely to experience unplanned ad-
missions. However, when adjustment is made for factorsincluding non-cardiovascular morbidity and drug burden,
we found no evidence of an increase in non-cardiovascular
admissions with increasing numbers of cardiovascular
medicines. Indeed, unplanned admissions were actually less
likely to occur in the context of higher levels of cardiovas-
cular prescribing, once other key factors had been adjusted
for. This may reflect the fact that much of the prescribing
of multiple cardiovascular medicines is driven by evidence-
based guidelines, and as such reflects appropriate rather
than problematic polypharmacy.
Strengths and limitations
Our study has a number of important strengths. These in-
clude the large study population, the use of high quality
data, and the linkage to secondary care data which helps
improve capture of hospital events. There are, of course, a
number of limitations. Firstly, we used a crude count of
cardiovascular medicines, and did not take into account
different drug classes or medication dose. However, our
sensitivity analysis employed an alternative measure of
polypharmacy based on drug classes and found similar re-
sults. Secondly, we were unable to factor in clinical indica-
tion for particular medicines. Nonetheless, we did include
a number of cardiovascular diagnoses in our analysis (with
an alternative approach used in the sensitivity analyses)
including an interaction term in the secondary analysis.
Thirdly, we used simple counts of non-cardiovascular
long-term conditions and medicines, and it may be that
results may differ if one looks at potential high-risk or
complex groups, such as heart failure patients receiving
non-steroidal anti-inflammatory drugs, or patients with
severe renal impairment unable to tolerate ACE inhibitors
or diuretics. More sophisticated measures, taking into
account appropriateness of drugs and clinical context,
Table 2 Adjusted logistic regression models for
unplanned non-cardiovascular hospital admission
Adjusted odds ratio (95% CI)
for unplanned admission
P value
Male 1.24 (1.18-1.30) <0.001
Age, years
20 to 39 Ref <0.001
40 to 59 0.84 (0.79-0.90)
60 to 79 1.10 (1.02-1.19)
80 or more 2.02 (1.84-2.22)
Deprivation quintile
1, least deprived Ref <0.001
2 1.11 (1.01-1.22)
3 1.19 (1.09-1.30)
4 1.28 (1.16-1.40)
5, most deprived 1.46 (1.33-1.61)
Cardiovascular condition
Hypertension 0.74 (0.69-0.80) <0.001
IHD 0.96 (0.87-1.06) 0.43
Stroke/TIA 1.81 (1.65-1.99) <0.001
PVD 1.15 (1.04-1.28) 0.009
Atrial fibrillation 1.12 (0.99-1.27) 0.075
Heart failure 1.07 (0.95-1.22) 0.26
Non-cardiovascular
comorbidity count
None Ref <0.001
1 1.85 (1.71-2.00)
2 2.74 (2.51-3.00)
3 3.36 (3.05-3.71)
4 4.16 (3.73-4.64)
5 or more 4.70 (4.21-5.25)
Non-cardiovascular drug
count
None Ref <0.001
1 to 3 1.15 (1.07-1.23)
4 to 6 1.50 (1.37-1.64)
7 to 9 1.91 (1.71-2.13)
10 or more 2.85 (2.54-3.19)
Cardiovascular drug count
None Ref <0.001
1 or 2 0.93 (0.86-1.01)
3 or 4 0.77 (0.70-0.86)
5 or 6 0.66 (0.57-0.75)
7 or more 0.77 (0.65-0.92)
IHD, ischaemic heart disease; TIA, transient ischaemic attack; PVD, peripheral
vascular disease; CI, confidence interval.
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macy, but to date consensus has not been reached around
appropriate definitions, and one needs to balance the
transparency and pragmatism of simple measures of poly-
pharmacy against more complex approaches. Fourth, the
analyses are based on data from 2006 to 2007, yet rates of
medication use may have increased in the interim. It is
possible that if this increase is also associated with more
inappropriate use, then we may have underestimated the
potential for adverse consequences. Finally, it could be ar-
gued that a more specific medicine-related outcome might
be more relevant, such as hospital admission for adverse
drug reactions. However, inappropriate polypharmacy can
be considered to reflect poorer care more generally (e.g.
non-adherence to clinical guidance, lack of continuity of
care), and as such might be expected to manifest in
broader measures of adverse outcome, of which un-
planned hospitalisation is one. We specifically did not
examine the association between cardiovascular medi-
cines and cardiovascular admissions as we believe that
this would be impossible to usefully interpret. For ex-
ample, a positive association between the two may be
due to patients on multiple cardiovascular medicines hav-
ing poorer health, whereas a negative association may be
due to more cardiovascular medicines reflecting better
care; a combination of these effects might also be possible.
Comparison with existing literature
Previous work has found associations between increasing
unplanned hospitalisation and increasing degrees of poly-
pharmacy [3-5]. However, this has not previously been
examined in the specific context of cardiovascular medi-
cines. Although non-cardiovascular admissions were
observed more frequently in those receiving more car-
diovascular medicines, this association was reversed
once key confounding factors had been adjusted for.
This negative association was attenuated once the inter-
action between cardiovascular disease and cardiovascu-
lar therapy was accounted for, suggesting some of the
observed effect is driven by people with cardiovascular
disease who are not receiving appropriate cardiovascu-
lar treatment, and are less well managed in general.
Nonetheless, the effect still persisted to a lesser degree,
and there are a number of potential explanations for this
observation. Firstly, it is possible that more cardiovascular
medicines may be associated with better clinical care
generally. This might be due to better attentiveness to
evidence-based practice for other clinical areas, that in-
creased follow-up for cardiovascular disease provides an
opportunity for clinicians to address non-cardiovascular
morbidities, or that more frequent medication reviews are
likely to occur with consequent optimisation of non-
cardiovascular therapy. A second possibility is that more
cardiovascular medicines may be associated with different
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Figure 2 Adjusted risk of unplanned admission. Adjusted odds ratios (95% confidence intervals) of unplanned non-cardiovascular hospital
admission for a given number of cardiovascular medicines.
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a higher awareness of preventative strategies against ad-
mission and be more proactive about contacting their GP
at other times. Finally, it may well be that some admis-
sions are associated with cardiovascular disease, but are
not coded as such [15], with examples including acute
kidney injury, complications of diabetes, and smoking-
related illness. It is seems unlikely that cardiovascular
polypharmacy is primarily responsible for reducing non-
cardiovascular admissions. It is also not possible to ex-
clude the possibility that cardiovascular polypharmacy
may be harmful in terms of unplanned admissions, but it
would appear that overall any harm is more than out-
weighed by the associated better clinical care. It is of
course possible that any such benefit would no longer be
observed if there were improvements in holistic care
not simply limited to those with specific long-term con-
ditions such as cardiovascular disease. We can contrast
the current findings with related work we have carried
out examining the general case, where we found that in-
creasing numbers of medicines was indeed associated
with increased unplanned admissions, albeit an effect
tempered in the context of increasing co-morbidity [5].
It is possible that our current findings differ from others’
work due to differences in the study populations and
statistical models employed, although previous work has
corrected for similar factors such as age, gender and co-
morbidity [3,4]. The differences between cardiovascular
and general cases seem more likely to be accounted for
by the more systematic and evidence-based nature of
prescribing for cardiovascular disease, compared with
medication use in other clinical areas. The current find-
ings confirm that it is essential to consider the clinical
context of polypharmacy, as well as providing clinicianswith some confidence that the considerable burden of
cardiovascular medications is in general not contribut-
ing to undesirable hospital admissions.
We corrected for a number of important confounding
factors in our analysis. Older people were more likely to
be admitted, reflecting the increased prevalence of long-
term conditions and frailty. Socioeconomic deprivation
was also associated with increased admissions. This is
probably due to general higher levels of ill-health, and
poorer resources in terms of coping strategies and support
networks [16]. With the exception of stroke, cardiovascu-
lar morbidity was not particularly strongly associated with
non-cardiovascular admissions. The weak associations ob-
served may reflect general frailty, and the stronger effect
found with stroke likely reflects complications of this con-
dition less commonly found with other cardiovascular
conditions, such as poor mobility and falls, or stasis pneu-
monia [17]. The negative association with hypertension
has been noted previously, and could be suggestive of
improved clinical monitoring in such patients [18]. It is
worth noting that the effect of cardiovascular morbidity
generally goes up in those patients not receiving any
cardiovascular drugs. Non-cardiovascular morbidity and
medicine count are both unsurprisingly associated with
increased admissions. Medicine count may in this circum-
stance either reflect increasing disease severity, or illness
not captured by the simple morbidity count. Of course,
there are numerous other factors related to prescribing
that we were unable to account for, beyond simply num-
ber of medications. These include physician adherence to
clinical guidelines, patient experience of care, potential ad-
verse effects and aspects of the doctor-patient relationship.
Some of these issues might be addressed through the use
of more sophisticated metrics of polypharmacy, and some
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factors certainly have the potential to modulate the effect
of polypharmacy that we observed.
Conclusions
This study has shown that cardiovascular polypharmacy
is common and suggests that adverse consequences, as
measured by unplanned hospital admissions, are not an
inevitable consequence of prescribing multiple medi-
cines. Crude measures of polypharmacy should therefore
not be used as quality metrics or as predictors of hos-
pital admission, and instead should take into account
clinical context. Further work is merited to determine
whether these observations vary between different car-
diovascular conditions, or across different clinical areas
where multiple prescribing is common.
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